Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of September 2025, with the specific transaction date being September 1, 2025. The filing details a share repurchase executed through the corporate stockbroker, Merrill Lynch International, as part of an existing buyback programme.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital allocation via share repurchases rather than operational financial performance. Key metrics for the transaction on September 1, 2025, include:
- Shares Purchased: 227,465 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,442.00p; highest price paid was 1,468.50p.
- Average Price: Volume-weighted average price paid was 1,451.50p.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, GSK holds 244,635,936 ordinary shares in treasury.
- Shares in Issue: 4,070,760,160 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.01% of the total voting rights.
Since the commencement of the current programme on June 4, 2025, the Company has purchased an aggregate of 26,501,553 ordinary shares.
Material Changes
The filing does not report material changes to revenue, profit, or operational margins. The primary change reported is the reduction in the number of shares in issue and the increase in treasury shares held by the Company. The percentage of voting rights attributable to treasury shares has increased to 6.01% following this transaction.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It references a non-discretionary agreement entered into with the broker on June 4, 2025, under which these purchases were effected. A standard cautionary statement regarding forward-looking statements is included, noting that actual results may differ materially from projections due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q2 Results for 2025.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since June 4, 2025 (26,501,553 shares).
- Confirm the current percentage of voting rights held in treasury (6.01%) for disclosure threshold calculations.
- Review the volume-weighted average price (1,451.50p) against the prevailing market price on September 1, 2025.
- Check the remaining capacity or authorization limits of the buyback programme initiated on June 4, 2025.